Childhood B-acute Lymphoblastic Leukaemia and Role of CD9 Gene Regulation in Relapse
Recruiting
N/A
Interventional Study
Leukemia, Lymphoblastic, Acute, Pediatric
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
At a Glance
- Age
- 0 – 17
- Sex
- Any
- Study type
- Interventional
- Purpose
- Basic Science
- Participants needed
- 50 (estimated)
- Sponsor
- Rennes University Hospital · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
B-acute lymphoblastic leukaemia (B-ALL) is the most common cancer in children, with 20% of patients relapsing. CD9, a transmembrane protein, is linked to the migratory and adhesion capacities of leukaemia cells and could be associated with relapses. The aim of this project is to understand how CD9 regulation can be a marker of potential relapses, using bone and blood sampling of newly diagnosed pa…
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* Under 18 years
* With established diagnosis of B-ALL
* Initial diagnosis made in the investigating centre
* Having received oral and written information about the protocol, or oral only if the patient is unable to read.
* Having signed a consent form if the patient is capable …
Contacts